The Public Summary Document of the Pharmaceutical Benefits Advisory Committee’s (PBAC) consideration of the interim report of the Post-market Review of Opioid Dependence Treatment Program medicines which was considered out-of-session between March 2023 and July 2023 by the PBAC is now available.